X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AJANTA PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AJANTA PHARMA PFIZER/
AJANTA PHARMA
 
P/E (TTM) x 34.6 22.9 151.0% View Chart
P/BV x 5.5 4.4 124.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 PFIZER   AJANTA PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
AJANTA PHARMA
Mar-18
PFIZER/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,3651,818 130.1%   
Low Rs1,6251,106 146.9%   
Sales per share (Unadj.) Rs430.3239.5 179.7%  
Earnings per share (Unadj.) Rs78.752.8 149.1%  
Cash flow per share (Unadj.) Rs93.259.5 156.6%  
Dividends per share (Unadj.) Rs20.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs586.5230.0 255.0%  
Shares outstanding (eoy) m45.7588.77 51.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.66.1 75.9%   
Avg P/E ratio x25.327.7 91.5%  
P/CF ratio (eoy) x21.424.6 87.1%  
Price / Book Value ratio x3.46.4 53.5%  
Dividend payout %25.40-   
Avg Mkt Cap Rs m91,271129,782 70.3%   
No. of employees `0002.66.8 38.7%   
Total wages/salary Rs m3,1433,765 83.5%   
Avg. sales/employee Rs Th7,484.83,128.4 239.3%   
Avg. wages/employee Rs Th1,195.0554.0 215.7%   
Avg. net profit/employee Rs Th1,369.1689.7 198.5%   
INCOME DATA
Net Sales Rs m19,68521,258 92.6%  
Other income Rs m1,143242 473.1%   
Total revenues Rs m20,82821,499 96.9%   
Gross profit Rs m5,0036,584 76.0%  
Depreciation Rs m663596 111.2%   
Interest Rs m44 102.4%   
Profit before tax Rs m5,4796,226 88.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8781,539 122.0%   
Profit after tax Rs m3,6014,686 76.8%  
Gross profit margin %25.431.0 82.1%  
Effective tax rate %34.324.7 138.7%   
Net profit margin %18.322.0 83.0%  
BALANCE SHEET DATA
Current assets Rs m24,16712,236 197.5%   
Current liabilities Rs m9,5443,461 275.8%   
Net working cap to sales %74.341.3 179.9%  
Current ratio x2.53.5 71.6%  
Inventory Days Days5560 91.5%  
Debtors Days Days2984 34.0%  
Net fixed assets Rs m9,51411,140 85.4%   
Share capital Rs m458177 258.6%   
"Free" reserves Rs m26,37520,237 130.3%   
Net worth Rs m26,83220,414 131.4%   
Long term debt Rs m2510 247.5%   
Total assets Rs m36,90024,486 150.7%  
Interest coverage x1,305.51,519.4 85.9%   
Debt to equity ratio x00 188.3%  
Sales to assets ratio x0.50.9 61.4%   
Return on assets %9.819.2 51.0%  
Return on equity %13.423.0 58.5%  
Return on capital %20.430.5 66.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2211,667 0.2%   
Fx outflow Rs m1,4891,616 92.2%   
Net fx Rs m-1,46610,052 -14.6%   
CASH FLOW
From Operations Rs m3,3182,854 116.2%  
From Investments Rs m-2,383-2,604 91.5%  
From Financial Activity Rs m-1,104-2 55,175.0%  
Net Cashflow Rs m-169248 -67.9%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 1.6 483.9%  
FIIs % 4.9 7.6 64.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 17.0 139.4%  
Shareholders   85,207 20,968 406.4%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SANOFI INDIA  ABBOTT INDIA  FDC LTD.  NATCO PHARMA  STRIDES PHARMA SCIENCE  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

PFIZER Announces Quarterly Results (3QFY19); Net Profit Up 51.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

PFIZER Announces Quarterly Results (2QFY19); Net Profit Down 13.8% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, PFIZER has posted a net profit of Rs 958 m (down 13.8% YoY). Sales on the other hand came in at Rs 5 bn (down 9.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Apr 18, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS